ADXS-HPV | Clinical Pipeline | Global BioPharma, Inc.

ADXS-HPV

ADXS-HPV immunotherapy is GBP main products. Such live-virus immunotherapy authorized from the U.S. Advaxis. ADXS-HPV immunotherapy can secrete a tumor-specific antigen containing the fusion protein LLO-E7. This immunotherapy technology can stimulate the body's immune system to recognize tumor antigens foreign to generate an immune response to attack cancer cells. This is a platform technology can be widely used, can be applied to the treatment of many types of cancer, infectious diseases and autoimmune diseases.

This technique involves the use of genetically engineered Listeria, which includes innate and acquired immune to create dual system, such as to induce antigen-specific antitumor immune response, increasing therapeutic immune response with a specific number of immune cells and mature, the establishment of a strong immune response. ADXS-HPV has been transformed into a very low toxicity live immunotherapy. Its virulence than the wild species of pathogenic hundred thousandth. In addition, this technique is more changes in tumor, making them more susceptible to immune system attack.ADXS-HPV in the 2012 World Vaccine Manufacturing Congress was awarded "Best being developed or marketed therapeutic immunotherapy" VIE Awards (Vaccine Industry Excellence Award). ADXS-HPV immunotherapy to develop treatments currently lack effective treatment for various cancers (cervical cancer, head and neck cancer, anal cancer, etc.) and associated precancerous lesions due to human papillomavirus(HPV) infection.